In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media

Pablo Yagupsky, O. Katz, N. Peled, R. Dagan

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background: In recent years, novel fluoroquinolones with improved activity against gram-positive organisms have been introduced into clinical practice. These drugs may be of potential benefit for the treatment of pneumococcal otitis media, including infections caused by organisms resistant to conventional drugs. Methods: In vitro activity of 6 fluoroquinolones against 77 pneumococcal isolates from middle-ear fluid was determined by the E test. Results: Resistance to penicillin, co-trimoxazole, erythromycin, clindamycin, and tetracycline was present in 59 (76.6%), 47 (61.0%), 19 (24.7%), 11 (14.3%), and 17 (22.1%) isolates, respectively. Fluoroquinolone MIC50 and MIC90 (inμg/ml) were as follows: ciprofloxacin: 1.0 and 3.0, levofloxacin: 0.75 and 1.0, sparfloxacin: 0.25 and 0.38, grepafloxacin: 0.25 and 0.38, trovafloxacin: 0.094 and 0.125, and moxifloxacin: 0.19 and 0.25, respectively. Conclusions: Novel fluoroquinolones and especially trovafloxacin and moxifloxacin appear to be of potential value for the treatment of acute otitis media caused by pneumococci resistant to traditional antibiotics.

Original languageEnglish
Pages (from-to)354-358
Number of pages5
JournalChemotherapy
Volume47
Issue number5
DOIs
StatePublished - 1 Dec 2001

Keywords

  • Antibiotic resistance
  • Children
  • Fluoroquinolones
  • Otitis media
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media'. Together they form a unique fingerprint.

Cite this